Industry Press Release
The American Epilepsy Society's Industry Press Releases page provides news from the industry as a courtesy to site visitors. Information contained within these documents has not been peer reviewed nor is it endorsed by the American Epilepsy Society.
Questions regarding these releases should be directed to information sources listed in the releases.
June 2013 - At CURE's 15th Annual Chicago Benefit, Guest of Honor Hillary Rodham Clinton Credits Breakthroughs in Research as Progress toward Cure for Epilepsy
Citizens United for Research in Epilepsy held their 15th annual Chicago Benefit at the Navy Pier Grand Ballroom on Thursday, June 13, 2013. More than 1,000 guests joined CURE founder and Chair Susan Axelrod and David Axelrod to support cutting-edge epilepsy research and raised nearly $1.5 million. The funds will go towards finding a cure for epilepsy.
This year's benefit was the most successful in CURE's history. Proceeds benefit research toward this critically underfunded disease.
For more from the evening:
Guest of Honor Hillary Rodham Clinton Addresses a Sold-Out Crowd at Navy Pier: http://bit.ly/198rDup
CURE Associate Research Director Tracy Dixon-Salazar, PhD, Discusses Impact of Her Daughter's Epilepsy: http://bit.ly/1ab3SDu
Susan Axelrod's Blog - Chair's Corner: http://bit.ly/1ab3SDu
June 2013 - Upsher-Smith Successfully Completes Phase III Study of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Epilepsy in Patients with Refractory Partial-Onset Seizures.
More information about the trial is available at www.clinicaltrials.gov (NCT01142193)
The open-label extension study can be found by searching NCT01191086 onwww.clinicaltrials.gov
For more information, visit www.upsher-smith.com
June 2012 - Lundbeck Encourages Epilepsy Community to Attend Upcoming Partners Against Mortality in Epilepsy (PAME) Conference
February 2010 - Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall
Optima Neuroscience Announces AES 2010 Auction Results
December 2010 - Optima Neuroscience Announces AES 2010 Auction Results
October 31 2010 - Tuberous Sclerosis Alliance
October 29 2010 - Novartis drug Afinitor
Medtronic September 2010
March 2010 - Medtronic
April 9, 2010 - Research Supporting the Role of Antiepileptic Drug Vimpat® (Lacosamide) (C-V) to be Highlighted at Upcoming AAN Meeting
March 12, 2010 - FDA Panel Recommends Approval with Conditions of Medtronic Deep Brain Stimulation Therapy for Patients with Refractory Epilepsy
March 11, 2010 - Newly-Published Study Reinforces Role of Antiepileptic Drug Vimpat® (lacosamide) (C-V) as an Add-on Treatment that Significantly Reduces Partial-onset Seizures in Adults with Epilepsy
February 1, 2010 - Astro-Med, Inc.’s Grass Technologies Donates Portable EEG System to Haiti Earthquake Relief
December 7, 2009 UCB - New Studies Support Use of Intravenous Vimpat (lacosamide) (C-V) in Hospital and Emergency Settings
December 7, 2009 UCB - New Data Support Long-term Use of Antiepileptic Drug Vimpat
December 6, 2009 Nihon Kohden America Announces the Auction of its Latest EEG Technology in Support of the AES Lennox and Lombroso Trust for Epilepsy Research and Training
August 21, 2009 Lundbeck Inc. Announces FDA Marketing Approval for Sabril
for the Treatment of Two Difficult-to-Treat Epilepsies
July 2009 Dilantin® (phenytoin sodium) 30 mg shortage
July 20, 2009 Astro-Med’s Grass Technologies Receives FDA Clearance to Market Its S12X Cortical Stimulator
June 1, 2009 FDA approves Lamictal®XR™; an extended-release once-daily, new generation treatment for epilepsy
May 11, 2009 FDA approves Lamictal® ODT™ Orally Disintegrating Tablets
May 11, 2009 Ortho-McNeil and Epilepsy Foundation Encourage People with Epilepsy to Submit Artwork to National Art Contest
May 26, 2009 UCB launches Vimpat® in the U.S. for add-on treatment of epilepsy in adults
April 29, 2009 Studies Uncover High and Often Overlooked Costs Associated with Epilepsy
April 10, 2009 New Keppra XRTM Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures
January 27, 2009 Epilepsia study demonstrates new add-on antiepileptic drug VIMPAT® (lacosamide) significantly reduces partial-onset seizures in adults with epilepsy
November 14, 2008 - Eisai FDA Approves BANZEL™ (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
October 29, 2008 - UCB’s Vimpat® approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults
September 15, 2008 -Keppra XR™ approved in the U.S.
Archived information is currently being updated